Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

Official title

Phase II Randomized Controlled Clinical Trial of Mitoxantrone Hydrochloride Liposome Combined With Irinotecan and Vincristine (VIM) With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

Overview

Explore the efficacy and safety of mitoxantrone liposome combined with irinotecan and vincristine (VIM) in the treatment of relapsed/refractory soft tissue sarcoma in children.

Detailed description

Children with relapsed/refractory soft tissue sarcoma who meet the inclusion criteria are randomly divided into VIM group and VIT group (irinotecan, vincristine, temozolomide) at 1:1. The efficacy and safety of the two groups are compared.

Interventions

• Drug Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine
  Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion , 4 cycles.
• Drug Temozolomide+Irinotecan+Vincristine
  Q3W, 4 cycles

Primary outcome measures

• Objective response rate (ORR) [Time frame: Up to 2 cycles of chemotherapy (each cycle is 21 days)]

Secondary outcome measures (4)

• Objective response rate (ORR) [Time frame: Up to 4 cycles of chemotherapy (each cycle is 21 days)]
• Disease control rate (DCR) [Time frame: Up to 4 cycles of chemotherapy (each cycle is 21 days)]
• Progression-free survival (PFS) [Time frame: From date of radomization unit the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 moths.]
• Overall survival (OS) [Time frame: From date of radomization unit the date of first documented date of death from any cause, assessed up to 24 moths]

Eligibility criteria

Inclusion criteria

• 2 years ≤age≤21 years, no gender limitation.
• The Karnofsky (≥16 years old) or Lansky (< 16 years old) physical status score is at least 70.
• The expected survival time is not less than 12 weeks.
• Heart function: a) Cardiac COLOR ultrasound detection LVEF≥ 50%; b) ECG suggests no myocardial ischemia; c) No history of arrhythmia requiring drug intervention before enrollment.
• Pathological results for patients of soft tissue sarcoma.
• Patients with rhabdomyosarcoma are limited to first -, second -, and third-line treatment, and patients with other pathological subtypes are limited to progression, recurrence, or refractory after first-line treatment, with refractory defined as failure to achieve complete or partial response to the most recent treatment.
• Measurable lesions (according to RECIST 1.1 standards, measurable lesions have not received radiotherapy, freezing and other local treatments).
• The patient must fully recover from the acute toxic effects of all previous anticancer chemotherapy.
• Good blood and organ function.
• During study participation, patients are able to adhere to outpatient treatment, laboratory monitoring, and necessary clinical visits.
• The parent/guardian of the child or adolescent subject is capable of understanding, agreeing to, and signing the study Informed consent (ICF) and the applicable child consent form prior to initiating any program-related procedures; Subject is capable of expressing consent with parental/guardian consent (if applicable).

Exclusion criteria

• Once received mitoxantrone or mitoxantrone liposomes.
• Patients who had received previous VIT (irinotecan + temozolomide + vincristine) chemotherapy.
• Previous treatment with adriamycin or other anthracyclines with a total cumulative dose of adriamycin > 360 mg/m\^2; Or patients with cardiac disease caused by previous anthracyclines.
• Receiving or not being able to discontinue P450 enzyme-induced anticonvulsant drugs (e.g., phenytoin, carbamazepine, etc.) within 4 weeks or 5 half-life periods prior to enrollment.
• Previous or concurrent clinical significance of active cardiovascular diseases.
• Severe chronic skin diseases in the past.
• Previous allergic asthma or severe allergic disease.
• Uncontrolled hypertension and diabetes.
• Have a history of other tumors, except cured cervical cancer or basal cell carcinoma of the skin.
• Active hepatitis B or hepatitis C infection.
• HIV or syphilis infected patients.
• Patients who have previously received organ transplants.
• Uncontrolled active systemic bacterial, viral, or fungal infection.
• Contraindications to high-dose hormone use, such as uncontrolled hyperglycemia, gastric ulcers, or psychiatric disorders.
• Severe neurological or psychiatric history, including epilepsy or autism.
• Pregnant, lactating women and patients of childbearing age who are unwilling to use contraception.
• Other circumstances deemed inappropriate by the investigator to participate in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Sun Yat-sen University Cancer Center — Guangzhou

Identifiers

NCT: NCT06514313 · CSPC-DED-STS-K01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗